Compressive Review about Taxol: History and Future Challenges

Lozano-Terol, G.; Sola-Martinez, R. A.; Cánovas-Díaz, M.; Diego Puente, Teresa de; Gallego Jara, Julia

Publication:
Compressive Review about Taxol: History and Future Challenges

dc.contributor.author	Lozano-Terol, G.
dc.contributor.author	Sola-Martinez, R. A.
dc.contributor.author	Cánovas-Díaz, M.
dc.contributor.author	Diego Puente, Teresa de
dc.contributor.author	Gallego Jara, Julia
dc.contributor.department	Bioquímica y Biología Molecular B e Inmunología
dc.date.accessioned	2023-10-16T22:10:54Z
dc.date.available	2023-10-16T22:10:54Z
dc.date.issued	2020-12-17
dc.description	© 2020. The authors. This document is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by /4.0/ This document is the Published version of a Published Work that appeared in final form in Molecules. To access the final edited and published work see DOI: 10.3390/molecules25245986
dc.description.abstract	Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to treat over one million patients, making it one of the most widely employed antitumoral drugs. Taxol® was the first microtubule targeting agent described in the literature, with its main mechanism of action consisting of the disruption of microtubule dynamics, thus inducing mitotic arrest and cell death. However, secondary mechanisms for achieving apoptosis have also been demonstrated. Despite its wide use, Taxol® has certain disadvantages. The main challenges facing Taxol® are the need to find an environmentally sustainable production method based on the use of microorganisms, increase its bioavailability without exerting adverse effects on the health of patients and minimize the resistance presented by a high percentage of cells treated with paclitaxel. This review details, in a succinct manner, the main aspects of this important drug, from its discovery to the present day. We highlight the main challenges that must be faced in the coming years, in order to increase the effectiveness of Taxol® as an anticancer agent.
dc.format	application/pdf	es_ES
dc.format.extent	24
dc.identifier.citation	Molecules 2020, 25, 5986
dc.identifier.doi	10.3390/molecules25245986
dc.identifier.issn	1420-3049
dc.identifier.uri	http://hdl.handle.net/10201/134828
dc.language	eng	es_ES
dc.relation.isreferencedby	ED_IDENTRADA=1176
dc.rights	info:eu-repo/semantics/openAccess	*
dc.rights	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	Drug;
dc.subject	Cancer;
dc.subject	Cell death;
dc.subject	Biotechnology
dc.subject	Antitumor agent
dc.title	Compressive Review about Taxol: History and Future Challenges	es_ES
dc.type	info:eu-repo/semantics/review	es_ES
dc.type	info:eu-repo/semantics/article
dspace.entity.type	Publication	es
relation.isAuthorOfPublication	b8be181a-7224-475a-8427-543751ef593c
relation.isAuthorOfPublication	0212fc0f-e15c-4b27-9a2d-116768a47044
relation.isAuthorOfPublication.latestForDiscovery	b8be181a-7224-475a-8427-543751ef593c